Reports are discounted or included with certain Membership Options.

Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Oct 2019| PHM220A| BCC Publishing

Report Overview

Report Highlights

This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.

Report Includes

Information on the top potential drug launches by pharma companies in 2019
Knowledge about drug, mechanism of action, and briefing of clinical evidences
Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
Insights into regulatory approvals, market scope, and analysis of pipeline molecules
Detailed profiles of the companies and competitors related to the industry

Report Scope

The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com

[+] Show Chapter Details

	Title/Chapter Name	Pages	Price	Member Price
	Full Report: Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry	127	$2,750	Free
	Chapter- 1: Introduction	3	Free Download	Free
Study Goals and Objectives Reasons for Doing This Study Scope of Report Information Sources Methodology Analyst's Credentials BCC Custom Research Related BCC Research Reports
	Chapter- 2: Significant Drug Launches	5	$250	Free
Table 1 : Potential Launches to Watch, 2019 Figure 1 : Percentage Distribution of R&D Spending for Clinical Development of Novel Drugs, by Therapeutic Category, 2019 Table 2 : Top Companies Investing in R&D, 2018 Figure 2 : Market Share Analysis of Major Players in the Global Pharmaceutical Industry, 2018 Table 3 : Potential Drug Launches, 2018
	Chapter- 3: Ultomiris (Ravulizumab)	11	$246	Free
Overview of Ultomiris Scientific Summary Disease Background Currently Available Treatment for PNH Pipeline Molecules for PNH Regulatory and Development Milestones of Ultomiris Market Scope for Ultomiris Company Profile
	Chapter- 4: Rinvoq (Upadacitinib)	17	$380	Free
Drug Overview Scientific Summary Disease Background Current Available Treatment for RA Pipeline Molecules Regulatory Status of Upadacitinib Market Scope for Upadacitinib Company Profile
	Chapter- 5: Drug XX	15	$335	Free
Drug Overview Scientific Summary Disease Background SMA Therapeutics Pipeline Currently Available Treatment for SMA Market Scope for Drug XX Company Profile
	Chapter- 6: Drug XX	10	$224	Free
Drug Overview Scientific Summary Disease Background Currently Available Treatment for AMD Pipeline Molecules for AMD Status of Regulatory Approval of Drug XX Market Scope for Drug XX Company Profile
	Chapter- 7: Drug XX	10	$224	Free
Drug Overview Scientific Summary Disease Background Regulatory Approval of Drug XX Current Available Treatment for MS Pipeline Molecules for MS Market Scope for Drug XX Company Profiles
	Chapter- 8: Drug XX	8	$179	Free
Drug Overview Scientific Summary Disease Background Regulatory and Development Milestones Currently Available Treatment for Psoriasis Pipeline Molecules Market Scope for Drug XX Company Profiles
	Chapter- 9: Drug XX	11	$246	Free
Drug Overview Scientific Summary Disease Background Regulatory and Development Milestones Currently Available Treatment Pipeline Molecules Market Scope for Drug XX Company Profile
	Chapter- 10: Drug XX	11	$246	Free
Drug Overview Scientific Summary Disease Background Currently Available Treatment for MS Pipeline Molecules of MS Regulatory and Developmental Milestones Market Scope for Drug XX Company Profile
	Chapter- 11: Drug XX	7	$157	Free
Drug Overview Scientific Summary Disease Background Management of Peanut Allergy Regulatory and Development Milestones Market Scope for Drug XX Company Profile
	Chapter- 12: Drug XX	13	$291	Free
Drug Overview Scientific Summary Disease Background Currently Available Treatment for Rheumatoid Arthritis Pipeline Molecules Market Scope for Drug XX Company Profile
	Chapter- 13: Conclusion	2	$45	Free
Figure 8 : Percentage Distribution of Drug Launches, by Therapeutic Category, 2019
	Chapter- 14: Appendix: Acronyms	4	$89	Free
Table 69 : Acronyms Used in This Report

FAQ

Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Single User License: $2750

Member Price: FREE

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

Thousands of recently published reports from select publishers

Member Discounts of up to 50% on over 20,000 additional reports from all publishers

Our analysts and research concierge for all inquiries